Regeneron Pharmaceuticals, Inc. (REGN) Financial Analysis and Rating

Comparison Analysis Based on SEC Data

Company Name Regeneron Pharmaceuticals, Inc.
Industry (SIC) 2834 - Pharmaceutical Preparations
Revenue in 2021 $16,072 million (ranked #20 out of 638 companies in the industry)
Assets as of 12/31/2021 $25,435 million (ranked #20)
Fiscal Year End December 31
Analyzed report 9/30/2021 (filed 11/04/2021)

Year:

Financial Position and Performance

Compared with Q3 2021 industry ratios Change during the quarter

better

unchanged
Compared with all listed companies

much better

Compare with a competitor

Financial Ratios Benchmarking

Finanancial Ratio Comparison of Q3 2021 company ratios
with industry ratios
(28 - Chemicals And Allied Products)
with all listed companies
Solvency Ratios
Debt ratio 
0.27
0.31
0.27
0.52
Debt-to-equity ratio 
0.37
0.22
0.37
0.57
Interest coverage ratio 
128.93
-9.21
128.93
2.37
Liquidity Ratios
Current Ratio 
3.71
5.08
3.71
2.01
Quick Ratio 
3.03
2.97
3.03
1.26
Cash Ratio 
1.56
4.37
1.56
0.88
Profitability Ratios
Profit margin 
47.3%
-124.4%
47.3%
4.2%
ROE (Return on equity), after tax 
40%
-50.6%
40%
-3.9%
ROA (Return on assets) 
28.7%
-30.4%
28.7%
0.9%
Activity Ratios
Asset turnover (days) 
602
1529
602
814
Receivables turnover (days) 
166
60
166
49
Resulting score +0,6 +1,2

Year:

Additional Ratios (not used to calculate the resulting score)

Finanancial Ratio Comparison of Q3 2021 company ratios
with industry ratios
(28 - Chemicals And Allied Products)
with all listed companies
Profitability Ratios
Gross margin 
85.7%
49.2%
85.7%
40.7%
Operating margin (Return on sales) 
53%
-24%
53%
9.3%
Activity Ratios
Inventory turnover (days) 
375
125
375
77
EBIT $1,831M
Price Ratios
Earnings per Share (basic) $15.37
Earnings per Share (diluted) $14.33

Auditor's Conclusion

We have performed a comparative analysis of the balance sheet and income statement of Regeneron Pharmaceuticals, Inc. (hereafter – the "Company") for the year 2021 as submitted to the U.S. Securities and Exchange Commission (SEC). The primary business activity of the Company is "Pharmaceutical Preparations" (SIC code 2834). In the analysis, we have compared the key financial ratios of the Company with the average (median) values of those ratios calculated for the specific industry sector and for all companies. The averages are calculated using data from the 2021 financial statements filed with the SEC through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). By comparing each of the eleven key metrics to the median, we have drawn a general conclusion about the quality of the company's financial condition. Calculations and summary conclusions are performed in a computerized manner using software and methodologies developed by ReadyRatios.

As a result of the analysis of the key financial ratios of the Company, we have established the following. The financial condition of Regeneron Pharmaceuticals, Inc. in 2021 is better than the financial condition of half of all companies engaged in the activity "Pharmaceutical Preparations"

Сompared with the average national ratios, the Company shows better results. The financial position of Regeneron Pharmaceuticals, Inc. is much better than that of most listed companies that submit financial statements to the U.S. Securities and Exchange Commission.

Financial Position and Performance History


More on Regeneron Pharmaceuticals, Inc.

Closest Competitors

Company USD ($), in Millions
Revenue Assets
Eli Lilly and Company 28,318 48,806
Viatris Inc. 17,886 54,843
Teva Pharmaceutical Industries Limited 15,878 47,666
Bausch Health Companies Inc. 8,434 29,202

See all industry leaders

Financial Data Source and Analysis Principles

The above is a comparative analysis of the company's financial position and performance. The comparison is based on official financial statements filed with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR) (about 10,000 largest publicly traded companies). The comparison is made using the eleven key financial ratios (see the table above). The company's financial ratios are compared with the median of the ratios for all companies and for companies in the same industry, as well as to the quartiles of these ratios. Each ratio value is assigned a score between -2 and +2 depending on its position relative to the quartiles (-2 – below the first quartile; -1 – between the first and the second quartile; +1 – between the second and the third quartile; +2 – above the third quartile; 0 – the ratio value deviates from the median by no more than 5% of the difference between the median and the quartile closest to the ratio value). To draw a conclusion from the analysis, the individual scores are weighted equally to produce an overall score ranging from -2 and +2.

much better (+1 - +2incl)
better (from 0.11 to +1incl)
about the same (from -0.11incl to +0.11incl)
worse (from -1incl to -0.11)
much worse (from -2incl to -1)
"Change during the year" calculation

Change during the year is calculated by comparing the resulting score of financial position within the industry with the last year's (quarter's) score. The result of the comparison may be as follows:

significantly improved (positive change of more than 1 point)
improved (positive change of less than 1 point)
unchanged (little or no change in score, no more than 0.11 points)
deteriorated (the score has decreased by less than 1 point during the year)
deteriorated significantly (the score has decreased by more than 1 point during the year)


Please note that this analysis does not indicate that the company's financial position is good or bad, but rather describes it in comparison to other U.S. businesses. For a detailed financial analysis, please use "ReadyRatios Financial Analysis" - load the data into the program>>

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: